biostudies-literatureUnknown148(2)Ocal OSirtexBayer HealthCareLudwig-Maximilians-Universität München<h4>Purpose</h4>To explore the potential correlation between baseline interleukin (IL) values and overall survival or objective response in patients with hepatocellular carcinoma (HCC) receiving sorafenib.<h4>Methods</h4>A subset of patients with HCC undergoing sorafenib monotherapy within a prospective multicenter phase II trial (SORAMIC, sorafenib treatment alone vs. combined with Y90 radioembolization) underwent baseline IL-6 and IL-8 assessment before treatment initiation. In this exploratory post hoc analysis, the best cut-off points for baseline IL-6 and IL-8 values predicting overall survival (OS) were evaluated, as well as correlation with the objective response.<h4>Results</h4>Forty-seven patients (43 male) with a median OS of 13.8 months were analyzed. Cut-off values of 8.58 and Journal of cancer research and clinical oncology475-485https://www.ebi.ac.uk/biostudies/studies/S-EPMC8800931biostudies-literatureBaseline Interleukin-6 and -8 predict response and survival in patients with advanced hepatocellular carcinoma treated with sorafenib monotherapy: an exploratory post hoc analysis of the SORAMIC trial.PMC8800931Ocal OBen Khaled NRicke JWildgruber MPech MBerg TBenckert JMorkunas EBasu BSangro BSengel CSeidensticker MGasbarrini AKlumpen HJPalmer DKupcinskas JMalfertheiner Pde Toni ENJurkeviciute GValle JWSeidensticker RSchutte KfalseBaseline Interleukin-6 and -8 predict response and survival in patients with advanced hepatocellular carcinoma treated with sorafenib monotherapy: an exploratory post hoc analysis of the SORAMIC trial.<h4>Purpose</h4>To explore the potential correlation between baseline interleukin (IL) values and overall survival or objective response in patients with hepatocellular carcinoma (HCC) receiving sorafenib.<h4>Methods</h4>A subset of patients with HCC undergoing sorafenib monotherapy within a prospective multicenter phase II trial (SORAMIC, sorafenib treatment alone vs. combined with Y90 radioembolization) underwent baseline IL-6 and IL-8 assessment before treatment initiation. In this exploratory post hoc analysis, the best cut-off points for baseline IL-6 and IL-8 values predicting overall survival (OS) were evaluated, as well as correlation with the objective response.<h4>Results</h4>Forty-seven patients (43 male) with a median OS of 13.8 months were analyzed. Cut-off values of 8.58 and 2022-01-01T00:00:00Z2022 Feb2026-05-09T20:21:08.956Z2022-02-11T15:37:30.549ZS-EPMC88009313385558510.1007/s00432-021-03627-1